US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

RXi Pharmaceuticals

0.3302

0.0000

Volume:- -

Turnover:- -

Market Cap:1.45M

PE:-0.11

High:0.3302

Open:0.3302

Low:0.3302

Close:0.3302

52wk High:7.70

52wk Low:0.3100

Shares:4.38M

Float Shares:2.30M

Volume Ratio:- -

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-3.0991

EPS(LYR):-5.5152

ROE:--

ROA:--

PB:0.44

PE(LYR):-0.06

Loading ...

Overview Company News Filings

Company Profile

Company Name:

RXi Pharmaceuticals

Exchange:

NASDAQ

Establishment Date:

- -

Employees:

- -

Office Location:

- -

Website:

http://www.rxipharma.com

Zip Code:

- -

Phone:

- -

Fax:

- -

Introduction:

RXi Pharmaceuticals Corporation, a clinical-stage RNAi company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents. Its clinical development programs include RXI-109, a self-delivering RNAi compound, which is in Phase IIa clinical trial that is used to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids; and a Phase I/II clinical trial in retinal scarring. It is also developing RXI-109 for the treatment of an ophthalmic indication, focusing on retinal and corneal scarring; and Samcyprone, a formulation of diphenylcyclopropenone, which is in Phase II clinical trial for the treatment of various disorders, such as warts, alopecia areata, non-malignant skin tumors, and cutaneous metastases of melanoma. In addition, the company is developing dermal scarring and wart programs with its sd-rxRNA technology. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/RXII/company"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"RXII","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RXII\",,,,,undefined,":{"symbol":"RXII","market":"US","secType":"STK","nameCN":"RXi Pharmaceuticals","latestPrice":0.3302,"timestamp":1542401999999,"preClose":0.3302,"halted":8,"volume":0,"delay":0,"changeRate":0,"floatShares":2300823,"shares":4376322,"eps":-3.099079,"marketStatus":"Trading","change":0,"latestTime":"02-12 11:29:01 EST","open":0.3302,"high":0.3302,"low":0.3302,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"ttmEps":-3.099079,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1770930000000},"marketStatusCode":2,"symbolChange":{"newSymbol":"PHIO","executeDate":"2018-11-19"},"adr":0,"adrRate":0,"exchange":"NASDAQ","adjPreClose":0.3302,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"RXII\",,,,,undefined,":{"symbol":"RXII","floatShares":2300823,"roa":"--","roe":"--","lyrEps":-5.515215,"shares":4376322,"dividePrice":0,"high":0.3302,"amplitude":0,"preClose":0.3302,"low":0.3302,"week52Low":0.31,"pbRate":"0.44","week52High":7.7,"institutionHeld":0,"latestPrice":0.3302,"eps":-3.099079,"divideRate":0,"volume":0,"delay":0,"ttmEps":-3.099079,"open":0.3302},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/RXII\",params:#limit:5,,,undefined,":[{"date":"2018-11-19","symbol":"RXII","newSymbol":"PHIO","type":"symbolChange","dateTimestamp":1542603600000},{"market":"US","date":"2018-11-14","symbol":"RXII","fiscalQuarterEnding":"2018/09","expectedEps":-0.45,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1542171600000,"reportTimeType":"post","actualEps":-0.34},{"market":"US","date":"2018-08-14","symbol":"RXII","fiscalQuarterEnding":"2018/06","expectedEps":-0.59,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1534219200000,"reportTimeType":"post","actualEps":-0.46},{"market":"US","date":"2018-05-10","symbol":"RXII","fiscalQuarterEnding":"2018/03","expectedEps":null,"name":null,"time":"Post Market","type":"earning","dateTimestamp":1525924800000,"reportTimeType":"post","actualEps":-0.9},{"market":"US","date":"2018-03-26","symbol":"RXII","fiscalQuarterEnding":"2017/12","expectedEps":-0.96,"name":null,"time":"","type":"earning","dateTimestamp":1522036800000,"reportTimeType":"","actualEps":-0.84}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"RXII\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"RXII\",market:\"US\",delay:false,,,undefined,":{},"@#url:\"stock.company.info\",,undefined,":{"stockCompanyProfile":{},"stockCompanyDetail":{"websiteUrl":"http://www.rxipharma.com","stockEarnings":[{"period":"1week","weight":0},{"period":"1month","weight":0},{"period":"3month","weight":0},{"period":"6month","weight":0},{"period":"1year","weight":0},{"period":"ytd","weight":0}],"compareEarnings":[{"period":"1week","weight":0.0084},{"period":"1month","weight":-0.0046},{"period":"3month","weight":0.0296},{"period":"6month","weight":0.0754},{"period":"1year","weight":0.1431},{"period":"ytd","weight":0.0147}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"RXi Pharmaceuticals Corporation, a clinical-stage RNAi company, focuses on discovering and developing therapies primarily in the areas of dermatology and ophthalmology. The company develops therapies based on siRNA technology and immunotherapy agents. Its clinical development programs include RXI-109, a self-delivering RNAi compound, which is in Phase IIa clinical trial that is used to prevent or reduce dermal scarring following surgery or trauma, as well as for the management of hypertrophic scars and keloids; and a Phase I/II clinical trial in retinal scarring. It is also developing RXI-109 for the treatment of an ophthalmic indication, focusing on retinal and corneal scarring; and Samcyprone, a formulation of diphenylcyclopropenone, which is in Phase II clinical trial for the treatment of various disorders, such as warts, alopecia areata, non-malignant skin tumors, and cutaneous metastases of melanoma. In addition, the company is developing dermal scarring and wart programs with its sd-rxRNA technology. The company was incorporated in 2011 and is headquartered in Marlborough, Massachusetts.","exchange":"NASDAQ","name":"RXi Pharmaceuticals","nameEN":"RXi Pharmaceuticals"}},"@#url:\"https://hq.skytigris.cn/fundamental/company/manager/list\",params:#symbol:\"RXII\",market:\"US\",,,undefined,":null}}